| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The 2009 A (H1N1) influenza virus pandemic: A review.
|
Vaccine
|
2010
|
3.28
|
|
2
|
A review of vaccine research and development: meningococcal disease.
|
Vaccine
|
2006
|
2.64
|
|
3
|
Protein-protein interactions between hepatitis C virus nonstructural proteins.
|
J Virol
|
2003
|
2.23
|
|
4
|
A review of human vaccine research and development: malaria.
|
Vaccine
|
2006
|
1.95
|
|
5
|
First generation leishmaniasis vaccines: a review of field efficacy trials.
|
Vaccine
|
2008
|
1.71
|
|
6
|
The impact of globalization on vaccine development and availability.
|
Health Aff (Millwood)
|
2006
|
1.58
|
|
7
|
A review of vaccine research and development: the human immunodeficiency virus (HIV).
|
Vaccine
|
2006
|
1.48
|
|
8
|
A review of vaccine research and development: human enteric infections.
|
Vaccine
|
2005
|
1.46
|
|
9
|
Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets.
|
Vaccine
|
2010
|
1.29
|
|
10
|
A review of vaccine research and development: human acute respiratory infections.
|
Vaccine
|
2005
|
1.27
|
|
11
|
Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.
|
PLoS Negl Trop Dis
|
2009
|
1.21
|
|
12
|
Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy.
|
PLoS Negl Trop Dis
|
2012
|
1.21
|
|
13
|
Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis.
|
J Gen Virol
|
2006
|
1.17
|
|
14
|
Global production capacity of seasonal influenza vaccine in 2011.
|
Vaccine
|
2012
|
1.17
|
|
15
|
Development and evaluation of influenza pandemic vaccines.
|
Lancet Infect Dis
|
2006
|
1.11
|
|
16
|
Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits.
|
Vaccine
|
2008
|
1.05
|
|
17
|
WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.
|
Vaccine
|
2011
|
1.05
|
|
18
|
Secondary structure of the 3' terminus of hepatitis C virus minus-strand RNA.
|
J Virol
|
2002
|
0.94
|
|
19
|
Hepatitis C virus IRES efficiency is unaffected by the genomic RNA 3'NTR even in the presence of viral structural or non-structural proteins.
|
J Gen Virol
|
2003
|
0.92
|
|
20
|
Cholera in disasters: do vaccines prompt new hopes?
|
Expert Rev Vaccines
|
2008
|
0.92
|
|
21
|
Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection.
|
J Virol
|
2002
|
0.89
|
|
22
|
Hepatitis C virus core, NS3, NS5A, NS5B proteins induce apoptosis in mature dendritic cells.
|
J Med Virol
|
2005
|
0.89
|
|
23
|
2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges.
|
J Infect Dis
|
2012
|
0.88
|
|
24
|
Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.
|
Vaccine
|
2011
|
0.87
|
|
25
|
Report of the third meeting on "influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007.
|
Vaccine
|
2008
|
0.86
|
|
26
|
Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009.
|
Vaccine
|
2009
|
0.86
|
|
27
|
Development of vaccines against influenza H5.
|
Lancet Infect Dis
|
2006
|
0.86
|
|
28
|
Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing World Health Organization--Organisation Mondiale de la Santé, Fondation Mérieux, Annecy, France, 7-9 January 2002.
|
Vaccine
|
2003
|
0.84
|
|
29
|
Reducing empiricism in malaria vaccine design.
|
Lancet Infect Dis
|
2010
|
0.84
|
|
30
|
Different approaches to influenza vaccination.
|
N Engl J Med
|
2006
|
0.83
|
|
31
|
Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice.
|
Cancer Gene Ther
|
2002
|
0.83
|
|
32
|
The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step.
|
Mol Pharmacol
|
2002
|
0.82
|
|
33
|
Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins.
|
Vaccine
|
2004
|
0.81
|
|
34
|
Analysis of the subcellular localization of hepatitis C virus E2 glycoprotein in live cells using EGFP fusion proteins.
|
J Gen Virol
|
2003
|
0.79
|
|
35
|
European Union conference on poverty-related diseases research.
|
Lancet Infect Dis
|
2009
|
0.78
|
|
36
|
The pandemic influenza vaccine challenge.
|
Vaccine
|
2008
|
0.78
|
|
37
|
Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008.
|
Vaccine
|
2008
|
0.78
|
|
38
|
Immunization safety priority project at the World Health Organization.
|
Semin Pediatr Infect Dis
|
2003
|
0.77
|
|
39
|
Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 6-7 December 2005.
|
Vaccine
|
2006
|
0.77
|
|
40
|
Recombinant CD63/ME491/neuroglandular/NKI/C-3 antigen inhibits growth of established tumors in transgenic mice.
|
J Immunol
|
2003
|
0.75
|
|
41
|
Reboot biomedical R&D in the global public interest.
|
Nature
|
2022
|
0.75
|